Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy

Pancreas. 2020 Oct;49(9):e93-e95. doi: 10.1097/MPA.0000000000001652.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Albumins / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics*
  • Circulating Tumor DNA / genetics*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease Progression
  • Female
  • Gemcitabine
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Paclitaxel / administration & dosage
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / genetics
  • Prognosis
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Survival Analysis

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Biomarkers, Tumor
  • Circulating Tumor DNA
  • KRAS protein, human
  • Deoxycytidine
  • Proto-Oncogene Proteins p21(ras)
  • Paclitaxel
  • Gemcitabine